Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Self-Driving EV and Tech — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while iShares Self-Driving EV and Tech trades at $36.18. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| ADPT | IDRV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $45.48 |
52-Week Low | $10.24 | $31.81 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IDRV trades at $38.51, up 2.01% today, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The ETF faces industry headwinds as rising fuel prices boost EV demand globally while US market adoption lags. Recent news highlights competitive threats from Chinese EV makers expanding internationally and regulatory uncertainty around US-China trade policies.
The ETF's outlook is challenged by sector volatility and geopolitical risks, though global EV adoption trends provide long-term growth potential. Key risks include tariff policy changes and slower-than-expected US EV adoption. Investors should monitor quarterly flows and sector performance for directional cues amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
